Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease

作者：Morales Vidal Sarkis^*; Schneck Michael J; Flaster Murray; Biller Jose

来源：Expert Review of Neurotherapeutics, 2012, 12(2): 179-190.

DOI：10.1586/ERN.11.185

• apixaban
• dabigatran
• direct factor Xa inhibitors
• direct thrombin inhibitors
• rivaroxaban
• stroke

Stroke is a leading cause of cardiovascular morbidity and mortality worldwide. Approximately, 795,000 strokes occur in the USA each year, 610,000 of which are first events, and 185,000 of which are recurrent events. Of all strokes, 87% are ischemic strokes. Novel anticoagulants serve as an alternative antithrombotic intervention in patients with ischemic cerebrovascular disease. This paper reviews the role of the novel anticoagulants, dabigatran, rivaroxaban and apixaban, in stroke prevention among patients with nonvalvular atrial fibrillation.

• 出版日期2012-2